Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 3385 2022-06-28 13:43:59 |
2 translation has been done Meta information modification 3385 2022-06-30 20:58:54 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Radziszewska, M.;  Smarkusz-Zarzecka, J.;  Ostrowska, L.;  Pogodziński, D. Nutrition and Supplementation in Ulcerative Colitis. Encyclopedia. Available online: https://encyclopedia.pub/entry/24577 (accessed on 08 July 2024).
Radziszewska M,  Smarkusz-Zarzecka J,  Ostrowska L,  Pogodziński D. Nutrition and Supplementation in Ulcerative Colitis. Encyclopedia. Available at: https://encyclopedia.pub/entry/24577. Accessed July 08, 2024.
Radziszewska, Marcelina, Joanna Smarkusz-Zarzecka, Lucyna Ostrowska, Damian Pogodziński. "Nutrition and Supplementation in Ulcerative Colitis" Encyclopedia, https://encyclopedia.pub/entry/24577 (accessed July 08, 2024).
Radziszewska, M.,  Smarkusz-Zarzecka, J.,  Ostrowska, L., & Pogodziński, D. (2022, June 28). Nutrition and Supplementation in Ulcerative Colitis. In Encyclopedia. https://encyclopedia.pub/entry/24577
Radziszewska, Marcelina, et al. "Nutrition and Supplementation in Ulcerative Colitis." Encyclopedia. Web. 28 June, 2022.
Nutrition and Supplementation in Ulcerative Colitis
Edit

Wrzodziejące zapalenie jelita grubego (UC) należy do grupy nieswoistych zapaleń jelit (IBD). WZJG jest nieuleczalnym, rozlanym i przewlekłym procesem zapalnym błony śluzowej okrężnicy z naprzemiennymi okresami zaostrzenia i remisji. 

ulcerative colitis colitis ulcerosa diet

1. Wstęp

Wrzodziejące zapalenie jelita grubego (UC) należy do grupy nieswoistych zapaleń jelit (IBD) [ 1 ]. WZJG jest nieuleczalnym, rozlanym i przewlekłym procesem zapalnym błony śluzowej okrężnicy z naprzemiennymi okresami zaostrzenia i remisji [ 2 , 3 ]. WZJG uznano za chorobę ogólnoświatową, ponieważ zachorowalność stale rośnie na całym świecie [ 2 ], przy czym najwyższa występuje w Europie Północnej, Kanadzie i Australii [ 3 ]. WZJG najczęściej rozpoznaje się w wieku od 30 do 40 lat [ 3 ]. Dokładna etiologia UC nie jest znana. Możliwe jest jednak, że czynniki genetyczne, immunologiczne i środowiskowe przyczyniają się do patogenezy choroby [ 4 , 5 ].
Najczęstszymi objawami UC są krwawe stolce [ 4 ]. Objawy towarzyszące mogą również obejmować parcie na stolec, obfite wydalanie śluzu z odbytu, zwiększoną częstotliwość wypróżnień, nocne wypróżnienia, dyskomfort w jamie brzusznej (ból, skurcze), nietrzymanie moczu, zmęczenie, gorączkę, odwodnienie i niedożywienie [ 3 , 4 , 6 ] . W badaniu palpacyjnym można zauważyć tkliwość, bolesność i wzdęcia brzucha, a także krew w badaniu odbytniczym [ 3 ]. Liczba oddanych stolców, a także obecność innych objawów może się różnić. Objawy mogą odzwierciedlać nasilenie zapalenia błony śluzowej jelit i rozległość zmian [ 3 , 4]. Ponadto wyniki przeprowadzonych badań mogą wykazywać oznaki anemii [ 4 ]. Najczęstszymi pozajelitowymi objawami są artropatia osiowa lub obwodowa, zapalenie twardówki i rumień guzowaty [ 4 ]. Ponadto pierwotne stwardniające zapalenie dróg żółciowych (PSC) jest rzadkim, ale złym prognostycznym powikłaniem UC. Pacjenci mają również zwiększone ryzyko zachorowania na raka jelita grubego [ 6 ].
Zgodnie z aktualnym stanem wiedzy nie ma złotego standardu w diagnostyce WZJG [ 6 ]. Obecnym markerem używanym do wykluczenia lub potwierdzenia IBD jest stężenie kalprotektyny w kale. Niskie poziomy tego wskaźnika wskazują na mniej niż 1% prawdopodobieństwa rozwoju IBD [ 3 ]. Ostateczna diagnoza opiera się na obrazie klinicznym, wynikach badań biochemicznych i histologicznych, a także endoskopowych, w tym kolonoskopii i rektoskopii u pacjentów z ciężkim zaostrzeniem choroby [ 4 , 6 ].
Forma leczenia UC jest dostosowana do ciężkości, dystrybucji i rodzaju choroby, w tym jej przebiegu, reakcji pacjenta na wcześniejsze leki i działania niepożądane, częstości nawrotów i objawów pozajelitowych. Istotnymi zmiennymi są również wiek pacjenta w momencie rozpoznania i czas trwania choroby [ 7 ]. Głównym celem leczenia jest uzyskanie remisji klinicznej potwierdzonej badaniem endoskopowym, bez konieczności rozpoczynania leczenia sterydami [ 6 ]. Leczeniem z wyboru w większości przypadków jest mesalazyna, do której u części chorych dołącza się wlew z aminosalicylanów [ 6 , 7 ]. W przypadku braku odpowiedzi do terapii włącza się kortykosteroidy ogólnoustrojowe, które są również zalecane u pacjentów z ciężkimi nawrotami WZJG [6 , 7 ]. Leki biologiczne lub immunosupresyjne stanowią alternatywną opcję leczenia pacjentów z WZJG, gdy poprzednie leki nie działały [ 7 ]. Chirurgia jest ostatecznym sposobem leczenia UC, stosowanym w przypadku niepowodzenia leczenia farmakologicznego i wystąpienia poważnych powikłań choroby [ 6 ].
Ze względu na specyfikę WZJG, poza leczeniem farmakologicznym i chirurgicznym, wprowadzenie odpowiednich nawyków żywieniowych i żywieniowych jest niezwykle ważnym elementem terapii, który jednak wciąż jest niedoceniany i często pomijany w praktyce medycznej [ 1 , 8 ]. Pomimo braku konkretnych porad dietetycznych w IBD, nawet ponad 70% chorych zauważa, że ​​nieodpowiednie odżywianie znacząco wpływa na przebieg choroby oraz zwiększa częstotliwość i nasilenie objawów [ 8 , 9 ]. W związku z tym pacjenci z UC intensywnie szukają wskazówek żywieniowych, aby poprawić jakość ich życia i przyczynić się do złagodzenia objawów [ 10]. Niestety, dotychczasowe badania nie dostarczają solidnych podstaw do stworzenia silnych, opartych na dowodach zaleceń dietetycznych [ 8 , 10 ]. Ciekawość pacjentów odnośnie diety i brak precyzyjnych zaleceń zmuszają ich do szukania informacji w Internecie i innych źródłach pozamedycznych [ 10 , 11 ].

2. Dieta wykluczająca wrzodziejące zapalenie jelita grubego (UCED)

Dieta eliminacyjna opracowana specjalnie dla pacjentów z UC również może być przyszłą, ale jeszcze niedostatecznie sprawdzoną dietą. Do tej pory jego skuteczność oceniano jedynie w prospektywnym, wieloośrodkowym badaniu pilotażowym przeprowadzonym w 2021 r., co stanowiło podstawę do dalszych badań [ 52 ]. UCED to podejście dietetyczne mające na celu modyfikację składu mikroflory jelitowej. Dieta ta wyklucza spożywanie produktów, które mogą niekorzystnie wpływać na komórki kubkowe, błonę śluzową jelit oraz skład mikroflory przewodu pokarmowego [ 52 ].]. UCED zmniejsza całkowite spożycie białka, szczególnie w celu zminimalizowania ekspozycji na aminokwasy zawierające siarkę, ogranicza spożycie tłuszczów zwierzęcych, nasyconych kwasów tłuszczowych i wielonienasyconych kwasów tłuszczowych, a także hemu i dodatków do żywności. Zamiast tego koncentruje się na zwiększonym spożyciu jednonienasyconych kwasów tłuszczowych, tryptofanu, pektyny i odpornej skrobi z naturalnych źródeł. UCED jest zatem dietą niskobiałkową, niskotłuszczową, bogatą w błonnik i eliminującą dodatki [ 52 ]. W pierwszej fazie diety, która trwa 6 tygodni, można podzielić produkty na te dopuszczone do spożycia w nieograniczonych i ograniczonych ilościach oraz te przeciwwskazane, co przedstawia  tabela 1 .. Natomiast w drugiej fazie, trwającej od 7 do 12 tygodnia, dieta daje pacjentowi większą swobodę wyboru. Wprowadzane są wybrane rośliny strączkowe, można spożywać większą różnorodność warzyw, zwiększa się spożycie produktów zbożowych [ 52 ].
Tabela 1.  Zalecane spożycie pokarmów w fazie 1 UCED [ 52 ].
Dozwolone w nieograniczonych ilościach Dozwolone w ograniczonych ilościach Przeciwwskazane
Warzywa Jajka czerwone mięso
Owoce Drób Przetworzona żywność
Ryż Jogurty Cukier
Ziemniaki Makaron
A study on UCED by Sarbagili-Shabat et al. included 24 pediatric patients diagnosed with exacerbation of UC (Paediatric Ulcerative Colitis Activity Index—PUCAI > 10) of mild or moderate form [52]. Patients followed the UCED diet for 6 weeks, then, if remission occurred, continued the diet for another 6 weeks. If patients did not improve by week 3 of the diet, or if they improved but relapsed between weeks 6 and 12, a 14-day course of antibiotics (amoxicillin, metronidazole, and doxycycline) was introduced. After the pharmacotherapy period, subjects were followed up for another 7 days [52].
Patients received training on the diet prior to the study and were given the necessary recipes for meal preparation and recommended menus. Patients were evaluated before dietary changes were made and again at weeks 3, 6, and 12. The efficacy of the diet was tested by assessing the PUCAI index, which reached values above 10 before dietary changes were implemented, whereas disease remission was confirmed when PUCAI < 10 [52]. Nutrient supply was assessed before the dietary changes and after the study period, and it was observed that there was a reduction in total protein intake, including sulfur-containing amino acids, iron, and saturated fatty acids, in favor of monounsaturated fatty acids and dietary fiber, according to the diet. Quantitative changes in the supply of the listed components are shown in Table 2.
Table 2. Changing the amount of nutrients consumed [52].
Nutrients Ingestion Prior to UCED Application Ingestion after 6 Weeks of UCED
Total protein 1.8 g/kg b.w./d 1.2 g/kg b.w./d
Cysteine 0.8 g/d 0.5 g/d
Methionine 1.6 g/d 0.9 g/d
Iron 12.1 mg/d 8.7 mg/d
Saturated fatty acids 19.5 g/d 8.3 g/d
Monounsaturated fatty acids 21.6 g/d 27.3 g/d
Dietary fiber 16.4 g/d 21.7 g/d
After 6 weeks of UCED, clinical remission was observed in nearly 37% of subjects. Some patients required additional antibiotic therapy and after 3 weeks of combined pharmacotherapy and diet, 50% achieved clinical remission. The average PUCAI value was reduced from 35 to 12.5 (pre-intervention value and at week 6, respectively). In contrast, median fecal calprotectin decreased from 818 μg/g to 592 μg/g, respectively. Thus, it is suggested that the UCED may be an effective way to induce remission in pediatric patients with mild to moderate UC [52]. While this study is promising, it is worth noting that larger studies should be conducted, particularly in adults. The first stage of the diet is very strict and limits the consumption of many foods, so it should be analyzed whether it negatively affects the nutritional status of the patient. In addition, it is a diet in which the intake of dietary fiber is increased, which is not always beneficial for patients with UC, especially during exacerbation, so it should be considered to analyze the intake of this component, especially in terms of its fraction provided with the diet. After careful consideration of all issues of dietary introduction, the group in whom it may be used, and the impact on patients’ clinical status, the UCED diet may be a suitable therapeutic tool in patients with UC.

3. Specific Carbohydrate Diet (SCD)

The SCD is one of the most common dietary approaches in IBD reported in the literature. However, the amount of evidence for the effectiveness of the SCD diet in controlling inflammation is still small [53]. This diet is based on the premise that polysaccharides and disaccharides, through low absorption in the gastrointestinal tract, cause imbalance of the intestinal microbiota and damage to the gut, which is the cause of celiac disease and IBD [54]. As a result of this thesis, processed and canned foods, milk, and most grains, including rice, corn, wheat, and barley, are excluded from the menu [54]. The main components of the diet are simple sugars, for example, fructose, glucose, and galactose. These carbohydrates are readily absorbed, thus counteracting excessive microbial growth in the gut and dysbiosis [53,54]. Fresh fruits and vegetables, nuts, yogurt, meat, and hard cheeses are some of the recommended sources of nutrients in the SCD diet [54]. The SCD diet was first used in the first half of the 20th century by Dr. Sidney Has to treat celiac disease in children [53]. The effect of dietary specific carbohydrates on inflammation in IBD was tested in a prospective case–control study by Suskind et al. [55]. The study included 12 children aged 10–17 years with mild to moderate IBD activity. All subjects included in the analysis were asked to follow the SCD for 12 weeks. Patients’ laboratory tests were analyzed before dietary changes and at weeks 2, 4, 8, and 12. After 12 weeks, the researchers noted that recruited patients had improved disease activity index (in UC patients, the mean PUCAI value decreased from 28.3 to 6.7), decreased C-reactive protein levels, and normalized serum albumin levels. In conclusion, the authors of this study suggest that this diet may have a positive effect on clinical assessment and laboratory findings in IBD patients and is likely associated with improved gut microbiota composition [55]. The beneficial effect of SCD on gut microbiota, in individuals diagnosed with IBD in remission, was also found in an analysis by Kakodkar et al. [56]. This study additionally noted that patients with IBD in remission following a diet of specific carbohydrates reported a reduction in symptom sensation, and the ability to suspend pharmacological treatment [56]. A prospective study in pediatric patients with Crohn’s disease was also conducted to examine the significance of SCD on clinical presentation and intestinal mucosal status [57]. Sixteen patients were included in the study and were followed up for 52 weeks. Patients’ clinical status, degree of disease activity (via the Pediatric Crohn’s Disease Activity Index—PCDAI, Harvey–Bradshaw scale, and Lewis scale), and mucosal status using capsule endoscopy were assessed before follow-up and at weeks 12 and 52. The results showed that the SCD has a great positive effect on the clinical picture and intestinal mucosal status in pediatric patients with CD [57]. Another large, survey-based study by Suskind et al. involving 417 adult and pediatric patients with IBD (43% were diagnosed with UC) found a positive effect of the SCD on the health status of the subjects [58]. Researchers observed a reduction in the frequency and intensity of disease symptoms, particularly in abdominal pain and the occurrence of diarrhea, improved laboratory results in 47% of respondents, and clinical remission was observed in 33% of subjects after 2 months of the SCD, with 42% of subjects experiencing remission after 6 and also after 12 months of the elimination diet [58]. It is noted that there are few studies on the effect of dietary specific carbohydrates on IBD, and most of the existing studies are specifically on children and Crohn’s disease [54]. Additionally, the application of the results of these studies is limited because they are either case studies or retrospective in nature. Studies have shown that the SCD may have a positive effect on IBD; however, larger prospective studies, particularly in adults, are needed to recognize the efficacy and safety of this diet [54,55,56].

4. Low FODMAP

FODMAPs are fermentable oligosaccharides, disaccharides, monosaccharides, and polyols that are not absorbed in the gastrointestinal tract and thus contribute to gastrointestinal symptoms [59]. Commonly, these compounds are found in fruits, honey (which contain fructose), dairy products (abundant in lactose), onions, garlic, and wheat (containing fructans), some grains, seeds, nuts, and legumes (rich in oligosaccharides), as well as fruits and vegetables and sugar-free products that are rich in polyols such as sorbitol, xylitol, and mannitol [60,61]. The use of this diet should always be under the close supervision of a dietician, as improper use can contribute to serious nutritional disorders [62,63]. The low FODMAP diet is divided into three phases. In the first phase, FODMAPs below the threshold value are eliminated, then a challenge trial is performed, i.e., the products eliminated in the first phase are included one by one, so as to determine the impact of the different types of FODMAPs and their amounts. Finally, the development of a long-term, individually tailored diet for the patient is carried out [63]. The low FODMAP diet has found application in the treatment of Irritable Bowel Syndrome (IBS) [62]. After incorporating the diet, patients noticed a reduction in symptoms such as abdominal pain, bloating, diarrhea, and constipation. IBD is often accompanied by symptoms typical of IBS, so the possibility of using the diet in this group of patients has been suggested [62].
The positive effect of a low FODMAP diet in relieving gastrointestinal symptoms associated with IBS was demonstrated in a prospective, randomized study conducted by Pedersen et al. [64]. In the study, 89 patients (including patients in remission or with mild to moderate exacerbations of IBD) were randomly assigned to either a FODMAP-restricted diet or a standard diet for 6 weeks. Finally, the results of 78 individuals recruited for the study were analyzed. It was noted that in those following an elimination diet, up to 81% of individuals achieved dietary change effects, compared with the normal diet group where a response was seen in 46% of individuals. After the intervention period, a definite decrease in the index assessing the occurrence of IBS symptoms was noted in those following the low FODMAP diet, compared with the other group. However, this was for patients in remission and not those with mild to moderate IBD exacerbation. The main improvements were a decrease in the time and severity of abdominal pain, a decrease in bowel frequency, and an improvement in stool consistency. Additionally, a greater improvement in the quality of life of IBD patients on a low FODMAP diet has been reported [64]. The benefit of including a low FODMAP diet in the course of IBD was also found in three retrospective case-control studies [65,66,67]. In a study conducted in Australia, in IBD patients following a low FODMAP diet, an improvement in symptoms such as abdominal pain and bloating, diarrhea, and gas was found in about one out of two patients analyzed [65]. Another retrospective study conducted in 49 patients suffering from IBD revealed that about 40% of individuals signal the full effectiveness of a long-term low FODMAP diet. The main complaints reported to improve were abdominal pain and bloating [66]. A recent review of the medical records of 88 people with IBD by Prince et al. showed that the inclusion of a low FODMAP diet not only reduces the severity of gastrointestinal complaints, but also has a positive effect on stool consistency and frequency of bowel movements [67]. These results show that a low FODMAP diet may be associated with relief of gastrointestinal complaints in patients with IBD, although it does not affect inflammation in the gut [54]. However, it is very important that elimination of products does not last for too long a period of time, as this can lead to nutrient deficiencies and malnutrition [53]. The diet is also unfavorable if applied long-term due to possible negative effects on the gut microbiota of individuals with IBD [53].
FODMAPs are prebiotics, which are nutrients for gastrointestinal microbes [68,69]. It is suspected that by eliminating products in the diet that provide these compounds, one is exposed to reduced food for the gut microbiota. This may reduce the production of short-chain fatty acids, which lower the pH in the lumen of the gastrointestinal tract, modulate the functioning of the immune system, and thus may have a positive effect on human health [69]. Two studies by Halmos et al. evaluated how diets with different FODMAP contents may affect the microorganisms present in the human gastrointestinal tract [68,70]. One of these randomized controlled trials compared the effects of a FODMAP-restricted diet and a standard “Australian” diet on colonic microbiota composition and biomarkers related to intestinal mucosal function, in subjects with established IBS (27 subjects) and a population of healthy subjects (6 subjects) [68]. Before the intervention, subjects were asked to record their typical diet for 7 days and a stool sample was collected from them for 5 days. Subjects were then randomly assigned to one of the groups, the first to follow a low FODMAP diet (average 3.05 g/d) for 21 days, and the second to follow a standard “Australian” diet containing FODMAPs (at an average of 23.7 g/d) for the same period of time. Throughout the intervention period, fecal collections were made, and comparative analysis of the collected materials was performed. The concentration of short-chain fatty acids, pH value, and the number and diversity of colonic microorganisms were checked. Higher pH values and lower bacterial counts were noted in subjects limiting FODMAP intake compared with those on a typical diet. Additionally, butyric acid bacteria and bacteria associated with normal mucosal structure were found to be more abundant in those on the standard diet than those in the low FODMAP group. Thus, from the results, it can be concluded that the introduction of restrictions on FODMAP consumption should be carried out carefully, with an evaluation of the pros and cons factors, because it may have a negative impact on the presence of microorganisms in the gastrointestinal tract that are beneficial to human health [68]. Another study led by Halmos et al. was conducted in patients with Crohn’s disease in remission [70]. As in the previous study, patients were randomly assigned to either a low FODMAP diet or a typical “Australian” diet for 21 days. For the last five days of each intervention, stool samples were collected from each subject and evaluated for pH values, fecal calprotectin and short-chain fatty acid concentrations, and the number of microorganisms colonizing the gut. In addition, the gastrointestinal symptoms present were recorded daily. Although there was no difference in pH, short-chain fatty acid concentration, or total microbial count between subjects on the low FODMAP diet and those on the standard “Australian” diet, a difference in microbiota diversity was noted. The FODMAP-restricting subjects had fewer butyric acid-producing bacteria and affected normal mucosal structure, compared with the other group. Differences in diet were not significant in fecal calprotectin concentrations, but gastrointestinal complaints were increased in those on the “Australian” diet. Thus, the results of this study show that the use of a low FODMAP diet for a prolonged period of time may contribute to dysbiosis, shows no effect on intestinal inflammation, and despite its potential positive effects on the symptoms of IBD, its use in this disease entity is not fully justified [70 ]. Przegląd badań Vandeputte et al. odkryli również, że ograniczenie spożycia FODMAP u osób z chorobami jelit może przyczynić się do zmniejszenia  liczby Bifidobacterium  i innych zmian w mikroflorze jelitowej porównywalnych z dysbiozą [ 69 ]. Nie ma jednak jednoznacznej odpowiedzi, czy zmiany te są nieodwracalne, czy też występują tylko w okresie silnego ograniczenia diety występującego w trakcie diety [ 69 ]. Podsumowując, pomimo obiecujących wyników diety low FODMAP w łagodzeniu objawów żołądkowo-jelitowych, dieta ta wymaga dalszych badań, aby zapewnić jej bezpieczeństwo u pacjentów z IBD.
Ustalenie dokładnych zaleceń żywieniowych dla pacjentów z IBD jest niezmiennie dużym wyzwaniem, ponieważ nie ma wystarczających badań, aby sugerować jednoznaczne stosowanie jakiejkolwiek obecnie popularnej diety. Pewne jest, że potrzebne są dalsze, szczególnie randomizowane, badania kliniczne, które mogłyby pomóc w lepszym zrozumieniu mechanizmów wpływu diety na IBD.
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , ,
View Times: 664
Revisions: 2 times (View History)
Update Date: 30 Jun 2022
1000/1000
Video Production Service